Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) 2025 Conference November 18, 2025 11:00 AM ET Company ParticipantsYuval Cohen - CEOConference Call ParticipantsFarzin Haque - AnalystFarzin HaqueHi, good afternoon, everyone. I'm Farzin Haque, one of the biotech analysts at Jefferies. It's my pleasure to introduce Yuval Cohen, CEO of Corbus Pharmaceuticals. This is a fireside chat format. Thank you for joining us today.Yuval CohenThank you for having us.Farzin HaqueFor those who may be new to the story, can yo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 ...

Summary of Corbus Pharmaceuticals Holdings FY Conference Call Company Overview - **Company**: Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) - **Location**: Norwood, Massachusetts - **Size**: Under 40 employees - **Pipeline**: Three assets - two in oncology and one in obesity [5][6] Key Pipeline Programs 1. CRB-701 (Nectin-four ADC) - **Mechanism**: Antibody-drug conjugate (ADC) targeting Nectin-four with MMAE as payload - **Differentiation**: Utilizes site-specific conjugation with a precise drug-to-antibody ratio (DAR) of 2, and a stable linker, reducing collateral damage compared to PADCEV [7][8][9] - **Clinical Data**: - Lower rates of peripheral neuropathy and skin toxicity compared to PADCEV - Emerging clinical efficacy shows promising results with overall response rates (ORR) of 33% and 47% in head and neck cancer, compared to PADCEV's 23% [11][15][16] - **Safety Profile**: Ocular toxicity is manageable and does not lead to treatment discontinuation [21][22] - **Next Steps**: A pivotal study is planned for mid-next year, aiming for a controlled study against physician's choice therapies [31][32] 2. CRB-913 (Obesity Treatment) - **Mechanism**: CB1 inverse agonist, designed to avoid neuropsychiatric adverse events by being peripherally restricted [42][45] - **Clinical Data**: Initial studies show promising weight loss results; a 90-day study in obese non-diabetics is set to start soon [50][51] - **Next Steps**: Results from the first clinical data expected before the end of the year, followed by a more extensive study [48][50] 3. CRB-601 (Solid Tumor Program) - **Mechanism**: TGF beta play, currently in dose escalation - **Uncertainty**: High-risk, high-reward potential; awaiting data from a similar drug by Pfizer [52][53] Financial Overview - **Cash Position**: Just under $180 million, providing runway into late 2028 [55] - **Funding**: Recent fundraising completed, ensuring financial stability for upcoming studies [56] Regulatory and Market Positioning - **FDA Fast Track Designation**: Received for CRB-701, facilitating expedited development [36] - **Market Opportunity**: Positioned in a favorable landscape for head and neck cancer treatments, especially as existing therapies are limited [18][35] Conclusion - **Focus**: The primary focus is on advancing CRB-701 through pivotal studies, with significant milestones expected in 2026 [56][58] - **Outlook**: The company is optimistic about the upcoming clinical data and market positioning, particularly in oncology and obesity treatment sectors [59]

Exhibit 99.1 Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Norwood, MA, November 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025. "This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025," said Yuval ...

Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75 million public offering, extending cash runway into 2028Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025 NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical ...

Core Insights - Corbus Pharmaceuticals (CRBP) was initially valued at around $100, leading to a favorable investment thesis for the company [1] Company Analysis - The company operates in the biotech sector, with a focus on clinical trials and drug development [1] - The author has a PhD in biochemistry and extensive experience in analyzing biotech companies, indicating a strong foundation for evaluating the company's potential [1] Investment Perspective - The article emphasizes the importance of understanding the science behind biotech investments to avoid pitfalls [1]

Group 1 - The article discusses Corbus Pharmaceuticals Holdings, Inc. and its focus on Nectin-4 targeting, with significant data expected in early 2025 [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Corbus Pharmaceuticals or the biotech industry [1][3][4]

Core Insights - U.S. stock futures showed a mostly positive trend, with Nasdaq futures increasing by over 1% on Friday [1] - Roku Inc experienced a significant decline in pre-market trading following its third-quarter earnings report [1] Company Performance - Roku reported third-quarter net revenue of $1.211 billion, reflecting a 14% year-over-year increase, surpassing the Street consensus estimate of $1.206 billion [2] - The platform revenue for Roku was $1.06 billion, up 17% year-over-year, while device revenue decreased by 5% to $146 million [2] - Roku shares fell by 5% to $94.99 in pre-market trading following the earnings report [2] Other Companies in Focus - SPS Commerce Inc saw a 32.1% drop in shares to $70.57 after mixed third-quarter results and lower fourth-quarter guidance [4] - Corbus Pharmaceuticals Holdings Inc's shares fell 16.4% to $13.74 due to a public offering announcement [4] - Onespan Inc's shares decreased by 16.1% to $13.02 after reporting disappointing third-quarter sales and lowering FY25 guidance [4] - Savers Value Village Inc's shares dipped 15% to $11.25 following worse-than-expected third-quarter sales and lowered FY25 GAAP EPS guidance [4] - GSI Technology, Inc. shares fell 14.1% to $9.50 after second-quarter results [4] - Newell Brands Inc's shares declined 13.1% to $4.10 due to downbeat third-quarter results and lowered FY25 guidance [4] - DexCom Inc's shares fell 12.1% to $59.97 after announcing third-quarter results [4] - Site Centers Corp's shares declined 11.2% to $7.44 ahead of its third-quarter earnings release [4] - Aptiv PLC shares fell 7.6% to $75.88 [4] - Ventas Inc shares declined 7.5% to $68.77 [4] - Cooper-Standard Holdings Inc's shares fell 6.3% to $33.52 after reporting disappointing third-quarter results and lowering FY25 sales guidance [4]

Core Insights - U.S. stock futures showed a mostly positive trend, with Nasdaq futures increasing by over 1% on Friday [1] - Roku Inc experienced a significant decline in pre-market trading following its third-quarter earnings report [1] Company Performance - Roku reported third-quarter net revenue of $1.211 billion, reflecting a 14% year-over-year increase, surpassing the Street consensus estimate of $1.206 billion [2] - The company's platform revenue reached $1.06 billion, up 17% year-over-year, while devices revenue fell to $146 million, down 5% year-over-year [2] - Roku shares dropped 5% to $94.99 in pre-market trading following the earnings announcement [2] Other Company Movements - SPS Commerce Inc saw a 32.1% decline in pre-market trading to $70.57 after mixed third-quarter results and lower fourth-quarter guidance [4] - Corbus Pharmaceuticals Holdings Inc's shares fell 16.4% to $13.74 due to a public offering announcement [4] - Onespan Inc's shares decreased by 16.1% to $13.02 after reporting disappointing third-quarter sales and lowering FY25 guidance [4] - Savers Value Village Inc's shares dipped 15% to $11.25 following worse-than-expected third-quarter sales and lowered FY25 GAAP EPS guidance [4] - GSI Technology, Inc. shares fell 14.1% to $9.50 after second-quarter results [4] - Newell Brands Inc's shares declined 13.1% to $4.10 due to downbeat third-quarter results and lowered FY25 guidance [4] - DexCom Inc's shares dropped 12.1% to $59.97 after announcing third-quarter results [4] - Site Centers Corp's shares declined 11.2% to $7.44 ahead of its third-quarter earnings release [4] - Aptiv PLC and Ventas Inc saw declines of 7.6% to $75.88 and 7.5% to $68.77, respectively [4] - Cooper-Standard Holdings Inc's shares fell 6.3% to $33.52 after reporting disappointing third-quarter results and lowering FY25 sales guidance [4]

Core Viewpoint - Corbus Pharmaceuticals Holdings, Inc. has announced a public offering of approximately $75 million, consisting of 4,744,231 shares of common stock priced at $13.00 per share and pre-funded warrants for 1,025,000 shares priced at $12.9999 each, with the offering expected to close on or about November 3, 2025 [1][2]. Group 1: Offering Details - The total public offering size is approximately $75 million before deducting underwriting discounts and estimated offering expenses [1]. - The exercise price of the pre-funded warrants is set at $0.0001 per share [1]. - Corbus has granted underwriters a 30-day option to purchase up to an additional 865,384 shares on the same terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the clinical development of Corbus' pipeline, as well as for working capital and other general corporate purposes [2]. Group 3: Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [5]. - The company's pipeline includes CRB-701, CRB-601, and CRB-913, targeting cancer and obesity treatments [5].